Traditional Chinese medicine composition, traditional Chinese medicine mixture and preparation method and application thereof
By preparing a traditional Chinese medicine mixture containing angelica, scutellaria baicalensis, ephedra, macadamia, bitter almond, patchouli and platycodon, the treatment problem of acute lung injury was solved, and the treatment effect was achieved with significant therapeutic effect without side effects.
Patent Information
- Application Number
- CN202510345193.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-03-24
- Publication Date
- 2025-07-15
AI Technical Summary
There is a lack of effective drugs for treating acute lung injury in the prior art, and the existing treatment methods have failed to significantly reduce the mortality rate of patients. Traditional Chinese medicine compositions have potential therapeutic advantages.
The Chinese medicine mixture is prepared by distillation, decoction, scutellaria baicalensis, ephedra, macadamia, bitter almond, patchouli and platycodon as raw materials. The Chinese medicine mixture is prepared by distillation, decoction, filtration, and concentration, and adjusting the pH to 4.5-6.5. The obtained Chinese medicine mixture is used to treat acute lung injury.
It significantly alleviates the pathological characteristics of acute lung injury, inhibits inflammatory response, and achieves significant efficacy without side effects.
Smart Images
Figure BDA0005324414630000031 
Figure BDA0005324414630000042
Abstract
Description
Technical Field
[0001] The present disclosure relates to the technical field of traditional Chinese medicine, for example, to a traditional Chinese medicine composition, a traditional Chinese medicine mixture, and their preparation methods and applications. Background Art
[0002] Acute lung injury (ALI) is caused by injurious factors (such as sepsis, endotoxin shock, acute respiratory distress syndrome virus, aspiration pneumonia, contusion, pulmonary embolism, etc.), resulting in damage to alveolar epithelial cells and capillary endothelial cells, causing diffuse interstitial and alveolar edema in the lungs. The clinical manifestations are respiratory distress, accompanied by intractable hypoxemia, decreased lung compliance, and diffuse inflammatory infiltration. In severe cases, it can directly transform into acute respiratory distress syndrome (ARDS). Its incidence rate is as high as 79 / 100,000 per year, and the mortality rate is as high as 30% - 40%. Currently, the clinical treatment methods for acute lung injury mainly include drug treatment and mechanical ventilation. Using a protective ventilator treatment strategy can be helpful for treating patients with acute lung injury, but it fails to effectively reduce the mortality rate of patients; drug treatment has a certain effect on controlling the disease, but there is still no effective treatment drug at present.
[0003] With the research progress of the anti-inflammatory and immune mechanisms of traditional Chinese medicine and its active ingredients, more and more traditional Chinese medicines are applied clinically. Traditional Chinese medicine has the characteristics of long-lasting and mild effects, small side effects, and significant improvement of clinical symptoms, which more meets the treatment needs of acute lung injury. Therefore, it is of great significance to study traditional Chinese medicine compositions for treating acute lung injury. Summary of the Invention
[0004] The purpose of the present disclosure is to overcome the deficiencies in the prior art and provide a traditional Chinese medicine composition, a traditional Chinese medicine mixture, and their preparation methods and applications, so as to at least achieve the effects of obvious curative effect and no side effects for acute respiratory infections.
[0005] The purpose of the present disclosure is achieved through the following technical solutions:
[0006] On the one hand, a traditional Chinese medicine composition is provided. The raw materials of the traditional Chinese medicine composition include Angelica dahurica, Scutellaria baicalensis, Ephedra sinica, Magnolia biondii, Armeniaca vulgaris var. ansu, Belamcanda chinensis, Pogostemon cablin, and Platycodon grandiflorum.
[0007] In some embodiments, by weight, the raw materials include 167 parts of Angelica dahurica, 167 parts of Scutellaria baicalensis, 111 parts of Ephedra sinica, 111 parts of Magnolia biondii, 167 parts of Armeniaca vulgaris var. ansu, 167 parts of Belamcanda chinensis, 167 parts of Pogostemon cablin, and 167 parts of Platycodon grandiflorum.
[0008] On the other hand, a traditional Chinese medicine mixture is provided. The traditional Chinese medicine mixture is prepared from the traditional Chinese medicine composition according to any one of the above embodiments.
[0009] On the other hand, a method for preparing the traditional Chinese medicine mixture as described in any one of the above embodiments is provided. The method includes: distilling Pogostemon cablin, Magnolia liliflora Desr., and Angelica dahurica with water to obtain a substrate solution and a distillate; mixing polysorbate 80 with the distillate to obtain a mixed solution; filtering the substrate solution to obtain medicinal residues and filtrate I; decocting the medicinal residues with water for the first time and then filtering to obtain filtrate II; decocting Scutellaria baicalensis Georgi, Ephedra sinica Stapf, Platycodon grandiflorus (Jacq.) A. DC., Belamcanda chinensis (L.) DC., and Armeniaca vulgaris Lam. var. ansu (Maxim.) Yü et Lu with water for the second time and then filtering to obtain filtrate III; combining filtrate I, filtrate II, and filtrate III and performing primary concentration to obtain a clear extract; refrigerating the clear extract and then centrifuging, taking the supernatant and performing re-concentration to obtain a concentrated solution; mixing potassium sorbate, stevioside, the mixed solution, and the concentrated solution evenly, adjusting the pH to 4.5 - 6.5, and then adding water to obtain the traditional Chinese medicine mixture.
[0010] In some embodiments, the relative density of the clear extract is 1.12 - 1.15.
[0011] In some embodiments, the refrigerating time is 12 - 24 h.
[0012] In yet another aspect, an application of the traditional Chinese medicine composition as described in any one of the above embodiments, or the traditional Chinese medicine mixture as described in any one of the above embodiments, or the method as described in any one of the above embodiments in the preparation of a drug for preventing and / or treating acute respiratory tract infections is provided.
[0013] In yet another aspect, an application of the traditional Chinese medicine composition as described in any one of the above embodiments, or the traditional Chinese medicine mixture as described in any one of the above embodiments, or the method as described in any one of the above embodiments in the preparation of a drug for relieving and / or treating acute lung injury is provided.
[0014] The beneficial effects of the present disclosure are:
[0015] 1. The traditional Chinese medicine composition and the traditional Chinese medicine mixture provided by the present disclosure can significantly relieve the pathological features of acute lung injury and inhibit the inflammatory response of acute lung injury.
[0016] 2. The traditional Chinese medicine composition and the traditional Chinese medicine mixture provided by the present disclosure can achieve the effect of obvious curative effect and no side effects on acute respiratory tract infections. Specific Embodiments
[0017] The technical solutions in some embodiments of the present disclosure will be clearly and completely described below. Apparently, the described embodiments are only a part of the embodiments of the present disclosure, rather than all of the embodiments. Based on the embodiments provided by the present disclosure, all other embodiments obtained by those of ordinary skill in the art belong to the scope of protection of the present disclosure.
[0018] Unless otherwise required by the context, throughout the specification and claims, the term "comprising" is construed in an open, inclusive sense, i.e., "including, but not limited to".
[0019] Hereinafter, terms such as "first", "second", etc. are for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the quantity of the indicated technical features. Thus, features defined with "first", "second", etc. may explicitly or implicitly include one or more of such features.
[0020] Example 1
[0021] 1. A traditional Chinese medicine composition, the raw materials of which include: 167 g of Scutellaria baicalensis Georgi, 167 g of Pogostemon cablin (Blanco) Benth., 111 g of Ephedra sinica Stapf, 167 g of Armeniaca vulgaris Lam. var. ansu (Maxim.) Yü et Lu, 111 g of Magnolia liliflora Desr., 167 g of Angelica dahurica (Fisch. ex Hoffm.) Benth. et Hook. f. ex Franch. et Sav., 167 g of Platycodon grandiflorus (Jacq.) A. DC., 167 g of Belamcanda chinensis (L.) DC.
[0022] 2. A traditional Chinese medicine mixture prepared from the above traditional Chinese medicine composition, and its preparation method is as follows:
[0023] Pogostemon cablin (Blanco) Benth., Magnolia liliflora Desr., and Angelica dahurica (Fisch. ex Hoffm.) Benth. et Hook. f. ex Franch. et Sav. are distilled with water, and about 250 ml of distillate is collected, and 5 ml of polysorbate 80 is added and stirred evenly to obtain a mixed solution for standby; the substrate solution after distillation is filtered to obtain medicinal residues and filtrate I for standby; the medicinal residues are decocted with 6 times the amount of water for 1 hour, and filtered to obtain filtrate II for standby; Scutellaria baicalensis Georgi, Ephedra sinica Stapf, Platycodon grandiflorus (Jacq.) A. DC., Belamcanda chinensis (L.) DC., and Armeniaca vulgaris Lam. var. ansu (Maxim.) Yü et Lu are decocted with 8 times the amount of water, and decocted three times, each time for 1 hour, and filtered to obtain filtrate III; filtrate I, filtrate II, and filtrate III are combined and concentrated into a clear paste with a relative density of 1.12 - 1.15 (50 °C), refrigerated for 12 - 24 hours, centrifuged, the supernatant is taken, concentrated to about 700 ml, 3 g of potassium sorbate, 3 g of stevioside, and the above mixed solution are added, stirred evenly, the pH is adjusted to 4.5 - 6.5, water is added to 1000 ml, stirred evenly, and then sub-packed to obtain the product.
[0024] Experimental Example 1
[0025] 1. Materials
[0026] 1.1 Drugs
[0027] The positive drug is dexamethasone (DEX), purchased from Chengdu Cohen Experimental Equipment Co., Ltd. (batch number: RH384135), and diluted with physiological saline to 2 mg / ml for standby.
[0028] 1.2 Animals
[0029] Forty-eight SPF-grade SD rats were purchased from Beijing Speifo Biotechnology Co., Ltd., male, with a body weight of 200 ± 20 g, certificate number: No.110324220104384668, license number: SCXK(Beijing)2019-0010. They were raised in a SPF-grade animal breeding room at a room temperature of 20 - 26 °C, humidity of 60% - 70%, with a 12-hour day-night alternating lighting, and free access to food and water. The feed was provided by the SPF-grade experimental animal room of Chengdu University of Traditional Chinese Medicine. All animal experiments complied with the "Guide for the Care and Use of Laboratory Animals" (2021-05) of the International Committee.
[0030] 2. Experimental methods and effect verification
[0031] Forty-eight SPF-grade SD rats with a body weight of 200 ± 20 g were taken. After 3 days of adaptive feeding, they were randomly divided into a blank group, a model group (LPS), low, medium, and high-dose groups of the traditional Chinese medicine mixture, and a positive drug group (dexamethasone), with 8 rats in each group. After anesthetizing the rats with inhaled isoflurane, the rats were instilled with LPS at 5 mg / kg through nasal drops to establish an acute lung injury (ALI) model, and the blank group was instilled with an equal volume of normal saline. The low, medium, and high-dose groups were respectively intragastrically administered with 5.5 g / kg, 11 g / kg, and 22 g / kg of the traditional Chinese medicine mixture (the 11 g / kg in the medium-dose group is equivalent to the clinical equivalent dose for a 60 kg adult), and the intragastric volume was 10 ml / kg; the positive group was intragastrically administered with dexamethasone at 2 mg / ml, and the intragastric volume was 10 ml / kg; the blank group and the model group were intragastrically administered with an equal volume of normal saline. The drugs were continuously administered for 7 days, and the body weight changes were detected. Finally, the rats were anesthetized with inhaled isoflurane.
[0032] 2.1 Rat body weight and organ index
[0033] After the rats were anesthetized and sacrificed, the wet weights of the lung, spleen, and thymus tissues of the rats and the body weights of the rats were weighed and recorded, and the body weight changes, lung index, spleen index, and thymus index were calculated. The results are shown in the following table:
[0034]
[0035]
[0036] Note: Compared with the model group, *p < 0.05, **p < 0.01.
[0037] It was found that LPS significantly hindered the growth and development of rats, but after treatment with the traditional Chinese medicine mixture, the body weight of the rats increased significantly. At the same time, after LPS treatment, the lung index of the rats increased significantly, while the spleen index and thymus index decreased significantly, suggesting that there may be pulmonary edema and immune dysfunction in ALI rats, and this phenomenon was significantly improved after treatment with the traditional Chinese medicine mixture. Therefore, the traditional Chinese medicine mixture can relieve the pathological characteristics of ALI rats induced by LPS.
[0038] 2.2 Blood routine of rats
[0039] Before sacrificing the rats, blood was collected from the abdominal aorta after anesthesia. 1 ml of EDTA anticoagulated blood was collected and detected by a hematology analyzer. The white blood cell count, neutrophil percentage, lymphocyte percentage, etc. were recorded. The results are shown in the following table:
[0040]
[0041] Note: Compared with the model group, *p < 0.05, **p < 0.01.
[0042] It was found that the traditional Chinese medicine mixture could significantly reduce the increase in white blood cell count caused by LPS. Compared with the blank control group, after treatment with the traditional Chinese medicine mixture, the percentages of peripheral blood neutrophils and monocytes in LPS-induced ALI rats increased, while the lymphocyte percentage decreased, indicating that the traditional Chinese medicine mixture could inhibit the inflammatory response in ALI rats.
[0043] In summary, the traditional Chinese medicine composition, traditional Chinese medicine mixture, their preparation methods and applications provided by the present disclosure can significantly relieve the pathological characteristics of acute lung injury and inhibit the inflammatory response of acute lung injury, achieving the effect of obvious curative effect and no side effects for acute respiratory infections.
[0044] The above are only the preferred embodiments of the present disclosure. It should be understood that the present disclosure is not limited to the form disclosed herein, should not be regarded as excluding other embodiments, but can be used in various other combinations, modifications and environments, and can be changed within the scope of the concept described herein through the above teachings or the technology or knowledge in related fields. And any changes and modifications made by those skilled in the art without departing from the spirit and scope of the present disclosure shall fall within the protection scope of the appended claims of the present disclosure.
Claims
1. A traditional Chinese medicine composition, characterized in that, The raw materials of the traditional Chinese medicine composition include Angelica dahurica, Scutellaria baicalensis, Ephedra sinica, Magnolia biondii, Armeniaca vulgaris var. ansu, Belamcanda chinensis, Pogostemon cablin and Platycodon grandiflorum.
2. The traditional Chinese medicine composition according to claim 1, wherein By weight, the raw materials include 167 parts of Angelica dahurica, 167 parts of Scutellaria baicalensis, 111 parts of Ephedra sinica, 111 parts of Magnolia biondii, 167 parts of Armeniaca vulgaris var. ansu, 167 parts of Belamcanda chinensis, 167 parts of Pogostemon cablin and 167 parts of Platycodon grandiflorum.
3. A traditional Chinese medicine mixture, characterized in that, It is prepared from the traditional Chinese medicine composition as described in Claim 1 or 2.
4. A method for preparing the traditional Chinese medicine mixture as described in claim 3, characterized in that, It includes: Distill the Pogostemon cablin, the Magnolia biondii and the Angelica dahurica by adding water to obtain a substrate solution and a distillate; Mix polysorbate 80 with the distillate to obtain a mixed solution; Filter the substrate solution to obtain medicinal residues and filtrate I; First decoct the medicinal residues by adding water and then filter to obtain filtrate II; Second decoct the Scutellaria baicalensis, the Ephedra sinica, the Platycodon grandiflorum, the Belamcanda chinensis and the Armeniaca vulgaris var. ansu by adding water and then filter to obtain filtrate III; Combine filtrate I, filtrate II and filtrate III and conduct preliminary concentration to obtain a clear paste; Refrigerate the clear paste and then centrifuge it, take the supernatant and conduct re-concentration to obtain a concentrated solution; Mix potassium sorbate, stevioside, the mixed solution and the concentrated solution evenly, adjust the pH to 4.5 - 6.5 and then add water to obtain the traditional Chinese medicine mixture.
5. The method according to claim 4, wherein The relative density of the clear paste is 1.12 - 1.
15.
6. The method according to claim 4, characterized in that, The refrigeration time is 12 - 24 h.
7. Use of the traditional Chinese medicine composition as described in Claim 1 or 2, or the traditional Chinese medicine mixture as described in Claim 3, or the method as described in any one of Claims 4 - 6 in the preparation of a drug for preventing and / or treating acute respiratory tract infection.
8. Use of the traditional Chinese medicine composition as described in Claim 1 or 2, or the traditional Chinese medicine mixture as described in Claim 3, or the method as described in any one of Claims 4 - 6 in the preparation of a drug for relieving and / or treating acute lung injury.